40
Participants
Start Date
October 31, 2015
Primary Completion Date
October 31, 2017
Study Completion Date
October 31, 2017
Ticagrelor 90 mg twice per day
Patients will be loaded with 180 mg of Ticagrelor during the enrollment office visit and provided with a 28 day supply of Ticagrelor, 90 mg twice per day. P2Y12 reactivity unit (PRU) testing will be conducted at 7-14 days. If the patient has a positive response, they will have the option of continued access of Ticagrelor 180 mg for another 2 months. Participants will be reminded via text message daily to complete a headache survey on line in order to track their headaches.
Columbia University Medical Center, New York
Collaborators (1)
AstraZeneca
INDUSTRY
Columbia University
OTHER